Canine Dendritic Cell Immunotherapy for Cytotoxic T Cell Generation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies, particularly in veterinary settings, lack effective methods for generating potent cytotoxic cells to combat cancer in canine patients, with existing technologies not fully leveraging the potential of antigen-presenting cells like dendritic cells for immunotherapy.
Innovation Solution
The method involves isolating peripheral blood mononuclear cells from canine cancer patients, culturing them to generate immature dendritic cells, and stimulating them with granulocyte-monocyte colony-stimulating factor and IL-4, followed by incubation with interferon gamma and activation via CD3 and CD28 receptors to induce tumoricidal activity, combined with the use of antigen-loaded dendritic cells and cytokines to enhance cytotoxic T cell and NK cell activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer therapies are used in veterinary settings, then treatment is provided, but effective methods for generating potent cytotoxic cells are lacking
Solution Approach 1:
Dendritic cells serve as intermediary antigen-presenting cells that bridge the innate and adaptive immune systems. These DCs are cultured ex vivo from canine peripheral blood mononuclear cells, loaded with tumor antigens, and used to stimulate the patient's own T cells to generate potent cytotoxic responses against cancer cells.
Solution Approach 2:
The therapy uses the patient's own immune cells (autologous approach) - canine peripheral blood mononuclear cells are cultured to generate dendritic cells that then stimulate the patient's own T cells. This self-service approach eliminates rejection issues and enhances the specificity and effectiveness of the anti-tumor response.
2Reliability
If antigen-presenting cells are utilized for immunotherapy, then immune response is enhanced, but the potential of dendritic cells is not fully leveraged
Solution Approach 1:
Dendritic cells are cultured ex vivo in advance and pre-loaded with tumor antigens before being administered to the patient. This preliminary preparation allows the DCs to be optimized for antigen presentation capability, ensuring maximum stimulation of cytotoxic T cells when introduced to the patient's system.
Solution Approach 2:
The culture conditions for dendritic cells are optimized with specific cytokines (GM-CSF, IL-4, interferon gamma) and activation signals (CD3 and CD28 receptor stimulation) to enhance their maturation and antigen-presenting capacity. These parameter changes transform immature DCs into highly effective immunostimulatory cells.
Data Source
AI summary
Described are compositions of matter, protocols, and treatment means for induction of immune mediated killing in dogs suffering from cancer. The invention provides means of extracting peripheral blood from a canine patient, expanding immunocytes capable of killing cancer cells in vitro, and re-administering said immunocytes into a patient in need of therapy. In one embodiment, immunocytes expanded are T cells possessing tumor cytotoxic activity induced by stimulation of NKG2D.